Honing in on the Motor Neuron Disease Lab's work ... We have also made, and are making, great advances in exposing the molecular underpinnings of the disease". When asked for the reason behind the lab ...

Aclipse Therapeutics LLC ("Aclipse" or "the Company") today announced that its M102 drug development program has been selected for presentations at the premier amyotrophic lateral sclerosis (ALS) and ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

In conclusion, this intriguing report builds on the work of many other groups by further unraveling MECP2 function in the ...

Poorly performing antibodies have plagued biomedical sciences for decades. Several fresh initiatives hope to change this.

Coordinated by the Chicago-based water innovation hub Current, in partnership with Argonne and the University of Chicago, ...

A recent study conducted in mice suggests that specific beneficial bacteria in a pregnant mother’s gut could support healthy ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

These devices could serve as valuable tools for biomedical research and may have potential for clinical applications in the ...